Chinese bear bile company courts controversy with IPO plan
This article was originally published in Scrip
A plan by a Chinese pharmaceutical company specialising in traditional medicines containing bear bile to seek a domestic stock listing has sparked strong opposition from animal welfare groups and members of the public.
You may also be interested in...
Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.
Collaboration with fundraising Tokyo-based venture builds mid-sized firm's interest in cell-based therapies in a highly supportive regulatory environment.
New long-term clinical data with Takeda’s dengue vaccine contender show a durable response against all four serotypes and support the dosing regimen in an ongoing pivotal study.